FDA Inspection
InvaGen Pharmaceuticals, Inc.InvaGen Pharmaceuticals, Inc. – FDA Inspection, Feb 9, 2026
Record Details
This FDA Inspection record concerns InvaGen Pharmaceuticals, Inc., with an inspection on February 9, 2026, issued by the New York District Office, covering human drugs.
View Company Profile
ID · 6f49afaf-f928-4ba0-a5bc-1df3f32d761d
Inspection Facts
- Inspection number
- 1302076
- FDA center
- Human Drugs
- Project area
- Generic Drug Evaluation
FDA Citations
2- 21 CFR 211.63Equipment Design, Size and Location
- 21 CFR 211.68(b)input/output verification
Full citation text and observation details available on the Dashboard.
Other FDA inspections of InvaGen Pharmaceuticals, Inc.
16| Date | Classification | Office | Project area |
|---|---|---|---|
| October 25, 2023 | NAI | Center for Drug Evaluation and Research | Drug Quality Assurance |
| December 6, 2019 | VAI | Center for Drug Evaluation and Research | Drug Quality Assurance |
| May 25, 2018 | VAI | Center for Drug Evaluation and Research | Drug Quality Assurance |
| March 30, 2017 | VAI | Center for Drug Evaluation and Research | Drug Quality Assurance |
| April 20, 2016 | NAI | Center for Drug Evaluation and Research | Bioresearch Monitoring |
Other documents for InvaGen Pharmaceuticals, Inc.
- FDA Inspection 1223321 - 2023-10-25
- FDA Inspection 1111971 - 2019-12-06
- FDA Inspection 1053263 - 2018-05-25
- FDA Inspection 1007073 - 2017-03-30
- FDA Inspection 970802 - 2016-04-20
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.